126 related articles for article (PubMed ID: 27459530)
1. Dopamine Agonists Can Reduce Cystic Prolactinomas.
Faje A; Chunharojrith P; Nency J; Biller BM; Swearingen B; Klibanski A
J Clin Endocrinol Metab; 2016 Oct; 101(10):3709-3715. PubMed ID: 27459530
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
3. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
4. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
5. Non-surgical management of cystic prolactinomas.
Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
7. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
8. First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.
Andereggen L; Frey J; Andres RH; Luedi MM; El-Koussy M; Widmer HR; Beck J; Mariani L; Seiler RW; Christ E
J Endocrinol Invest; 2021 Dec; 44(12):2621-2633. PubMed ID: 33847973
[TBL] [Abstract][Full Text] [Related]
9. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience.
Yedinak CG; Cetas I; Ozpinar A; McCartney S; Dogan A; Fleseriu M
Endocrine; 2016 Oct; 54(1):191-197. PubMed ID: 27460005
[TBL] [Abstract][Full Text] [Related]
11. Management of cystic prolactinomas: a review.
Nakhleh A; Shehadeh N; Hochberg I; Zloczower M; Zolotov S; Taher R; Daoud Naccache D
Pituitary; 2018 Aug; 21(4):425-430. PubMed ID: 29654440
[TBL] [Abstract][Full Text] [Related]
12. Influence of age on the clinical presentation of prolactinomas in male patients.
Delgrange E; Maiter D; Donckier J; Tourniaire J
Gerontology; 1999; 45(3):160-4. PubMed ID: 10202261
[TBL] [Abstract][Full Text] [Related]
13. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
14. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
15. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
16. Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas.
Park JY; Choi W; Hong AR; Yoon JH; Kim HK; Jang WY; Jung S; Kang HC
Pituitary; 2021 Dec; 24(6):955-963. PubMed ID: 34189717
[TBL] [Abstract][Full Text] [Related]
17. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment.
Ribeiro RS; Abucham J
Eur J Endocrinol; 2009 Jul; 161(1):163-9. PubMed ID: 19359408
[TBL] [Abstract][Full Text] [Related]
18. Role of gamma knife radiosurgery in the treatment of prolactinomas.
Ježková J; Hána V; Kosák M; Kršek M; Liščák R; Vymazal J; Pecen L; Marek J
Pituitary; 2019 Aug; 22(4):411-421. PubMed ID: 31222579
[TBL] [Abstract][Full Text] [Related]
19. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients.
Kreutzer J; Buslei R; Wallaschofski H; Hofmann B; Nimsky C; Fahlbusch R; Buchfelder M
Eur J Endocrinol; 2008 Jan; 158(1):11-8. PubMed ID: 18166812
[TBL] [Abstract][Full Text] [Related]
20. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
